It seems the pendulum is always swinging back and forth with the management of COPD. Few years ago, we have pulled away from the use of high dose inhaled corticosteroids when we found its association with increased risk of pneumonia and related mortalities. Here’s my post on this topic. And thus, the treatment strategy has shifted to using more long acting bronchodilators. These bronchodilators include LABA (long acting beta agonist) and LAMA (long acting muscarinic antagonist).
The American Psychiatry Association has just released new practice guidelines for the pharmacological treatment of patients with alcohol use disorder. For the full guidelines, click here. In this guideline, the use of these 5 agents have been discussed: naltrexone, acamprosate, disulfiram, topiramate and gabapentin.
As 2017 comes to an end, I want to reflect on some of the highlights for my blog.
First, here are my top 10 most commonly viewed posts or pages:
I am happy to see some of my patients’ opioid therapies being tapered down. Last week, I went to a talk on Opioid Use Disorder. The speaker described the opioid withdrawal symptoms as “oozing from the orifices”. I agree this description wholeheartedly! When opioids are tapered too quickly, it can cause tearing eyes, runny nose and diarrhea…..
If you live in Ontario, OHIP Plus will be effective as of Jan 1, 2018 which means the Ontario Drug Benefits Program will pay for a number of prescription medications for anyone below the age of 25. So what do you really need to know?
Recently, many primary health providers have been bombarded with questions about the latest shingles vaccine, Shringrix made by GlaxoSmithKline.
Pharmacists have finally developed the following 6 things to question in partnership with Choosing Wisely Canada: